Cell Line Refinement Strategy

To gain comprehensive insights into the practices of major players in biopharmaceutical development and manufacturing, it is essential to understand their methodologies and the underlying reasons behind them. One crucial aspect is the scientific focus of Contract Development and Manufacturing Organizations (CDMOs). Many CDMOs employ off-the-shelf media, cells, and equipment systems. This approach stems from the larger players’ aim to develop media that caters to a wide market, seeking products with broad market appeal. In other words, they offer materials that are deemed “sufficient” for various purposes. This strategy serves as a baseline and holds its own value, considering the demand for such materials.

However, the question we must address is whether we can strive for improvement. The answer is affirmative – we can indeed achieve better outcomes and should actively pursue them. Deepen your understanding of the development process for a high-quality cell line by engaging in an enlightening discussion featuring Mike Stewart, Chief Operations Officer, and Trent Lyman, Director of Process Development at Matica Bio.

Download the whitepaper to learn more about our cell line development strategy.

Get Your Copy